India, April 13 -- Allogene Therapeutics, Inc. (ALLO), a clinical-stage biotechnology company, reported data from the planned interim futility analysis of its pivotal, randomised Phase 2 ALPHA3 trial of Cemacabtagene ansegedleucel (Cema-Cel) in first-line consolidation of large B-cell lymphoma (LBCL).
Following the news, ALLO is up 44.12%, up $3.95.
Phase 2 ALPHA3 Interim Findings
This interim futility analysis was based on the first 24 patients randomised as 12 in the cema-cel arm and 12 in the observation arm and followed for post-treatment minimal residual disease(MRD) assessment.
MRD is assessed on Day 45, Month 3, and every 3 months during the first year of follow-up. The primary endpoint of EFS, along with key secondary endpoints ...